6% reported weight loss · 2.4% loss with placebo · 16 weeks
0.2 mg three times daily
Chinese adults with overweight or obesity without diabetes
Primary MMRM using model-predicted missing values; FAS 420. Approved in China for adult weight management under Feisumei since July 2023; also marketed for adult type 2 diabetes under Yishengtai.
Safety context
Nausea 49.3%; adverse-event discontinuations 5.9% vs 0.7% placebo.
Limitations: 16-week trial; 427 randomized, 420 analyzed; benaglutide is a spelling variant, not a separate asset.
Status in this atlas: Approved in China for adult weight management under Feisumei since July 2023; also marketed for adult type 2 diabetes under Yishengtai. Status source
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Source-provided sequence and chemical modification diagram of Beinaglutide.
Shown: Active peptide; formulation excluded.
A two-dimensional sequence diagram, not a three-dimensional conformation. Amino-acid abbreviations stand for residues; connecting lines represent peptide connectivity. This drug’s 30-residue sequence is human GLP-1(7–36), with the terminal form drawn as represented in the drug record.
